Table 1 Baseline characteristics

From: Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study

Patient Characteristics

Patients (n = 30)

Age, years

 Median

51.5 (39.5–57.0)

Tumor size, cm

 Median

4.6 (4.2–5.2)

 ≥4 to <4.5

13 (43.3%)

 ≥4.5 to <5

5 (16.7%)

 ≥5 to <6

8 (26.7%)

 ≥6

4 (13.3%)

Histologic type

 Squamous cell carcinoma

28 (93.3%)

 Adenocarcinoma

2 (6.7%)

PD-L1 status

 CPS < 1

1 (3.3%)

 1 ≤ CPS < 10

5 (16.7%)

 10 ≤ CPS < 50

7 (23.3%)

 CPS ≥ 50

17 (56.7%)

ECOG-PS score

 0

24 (80.0%)

 1

6 (20.0%)

FIGO 2018 stage

 IB3

11 (36.7%)

 IIA2

19 (63.3%)

SCC-Ag, ng/mL

 Median

5.2 (3.0–15.0)

HPV

 16 and/or 18

17 (56.7%)

 Negative

2 (6.6%)

 Not available

11 (36.7%)

  1. Data are n (%) or median (IQR). HPV human papillomavirus, SCC-Ag squamous cell carcinoma-related antigen, FIGO International Federation of Gynecology and Obstetrics, PD-L1 programmed cell death-1, CPS combined positive score, ECOG-PS Eastern Cooperative Oncology Group performance status
Back to article page